Full-Time

Senior Preclinical GLP QA Auditor

Posted on 11/15/2025

Altasciences

Altasciences

1,001-5,000 employees

Integrated CRO for early-phase drug development

No salary listed

Dunmore, PA, USA

In Person

Category
QA & Testing (1)
Requirements
  • Bachelor degree or higher in a scientific discipline, or equivalent combination of education and experience.
  • 2-3 years of related technical experience and/or training.
  • 2+ years experience auditing in a GLP-regulated environment.
  • Professional certification such as RQAP-GLP (Registered Quality Assurance Professional-GLP) or ASQ-CQA (American Society of Quality– Certified Quality Auditor) or other certification is recommended.
  • Training needs for this position include on-the-job training in performing audits and inspections, and independent reading of professional articles, journals and internal SOPs. Attendance at training seminars, regional and national meetings in Quality Assurance, regulatory affairs and validation, along with continual GLP training.
Responsibilities
  • Audits phases of nonclinical and laboratory studies, reports, and performs related duties (e.g., issues audits and QA statements) to ensure regulatory compliance.
  • Audits all disciplines (examples of disciplines include Method Validations, Non- Clinical GLP Studies).
  • Performs in-life audits, process audits, vendor qualifications, equipment and software validation audits.
  • Performs facility audits to ensure that the facility is in compliance with regulations.
  • Acts as lead auditor on studies and projects.
  • Maintains computerized files to support audit activities.
  • Supports project planning and implementation.
  • Provides risk-based compliance opinions and guidance.
  • Writes and issues inspection reports. Works with internal clients to ensure that inspection findings are clearly communicated and understood. Evaluates inspection finding responses to ensure they are written to address the findings appropriately.
  • Ensures through phase and data inspections that the SOPs, which are involved in the conduct of a study, are current and practiced.
  • Identifies and communicates opportunities for process improvements based on audit and inspection observations. Participates in and guides process improvement activities in both small intradepartmental groups as well as complex and possible multi-departmental interactions.
  • Maintains necessary documentation of QA records and study files.
  • Notifies management of observed quality and compliance trends in the areas inspected.
  • Autonomously performs SOP QA review, client hosting, regulatory agency hosting and external test site/clinical site/bioanalytical laboratory qualifications.
  • Under supervision of a mentor/coach, performs the following tasks: interpretation of FDA, regulations; project management; regulatory guidance review; quality issue investigations; and QA data collection, trending and analysis.
  • Recommends modifications in procedures to fit special needs or problems and involves manager when assistance in process improvement/resolution is necessary.
  • Interprets and can train on GLP and associated regulatory documents to facilitate auditing and process improvement recommendations.
  • Carries out appropriate self-development efforts as directed.
  • Assists with regulatory training of staff.
Desired Qualifications
  • Professional certification such as RQAP-GLP (Registered Quality Assurance Professional-GLP) or ASQ-CQA (American Society of Quality– Certified Quality Auditor) or other certification is recommended.

Altasciences provides an integrated CRO that handles the full early‑phase drug development path, from preclinical testing through clinical proof of concept and into manufacturing. Its approach combines discovery support, safety testing, clinical trial execution, and in‑house manufacturing to run programs under one roof. This contrasts with competitors that require pharma and biotech clients to source services from multiple vendors, adding complexity and risk; Altasciences streamlines the process by coordinating all steps. The company aims to help innovator drug programs move quickly and efficiently, delivering integrated data to de‑risk decisions and speed progression to later stages.

Company Size

1,001-5,000

Company Stage

Early VC

Total Funding

$6.7M

Headquarters

Laval, Canada

Founded

1976

Simplify Jobs

Simplify's Take

What believers are saying

  • Biotech/pharma consolidation demand for single-vendor early-phase development solutions increases.
  • 3D tissue technology adoption reduces animal testing costs and accelerates regulatory approval timelines.
  • Geographic footprint and participant database enable rapid enrollment for mid-size biopharma sponsors.

What critics are saying

  • Novo Holdings divesting Altasciences signals poor financial performance and operational cutbacks.
  • Charles River aggressive pricing on integrated packages captures 20% mid-size biopharma contracts.
  • AI-driven preclinical platforms from Insilico Medicine displace traditional animal safety pharmacology testing.

What makes Altasciences unique

  • Integrated CRO/CDMO spanning preclinical safety testing through Phase IV bioanalysis and manufacturing.
  • 9 North American facilities with 500,000+ participant database conducting 285+ trials annually.
  • VoxCell partnership integrates 3D tissue technology for human-relevant preclinical testing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Employee Assistance & Telehealth Programs

Remote Work Options

Company News

GlobeNewswire
Mar 16th, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard...

Business Wire
Aug 20th, 2025
Altasciences Receives EcoVadis Gold Medal for Environmental, Social, and Governance (ESG) Efforts

EcoVadis, the world's most trusted provider of business sustainability ratings, has collaborated closely with Altasciences to enhance its environmental, social, and governance (ESG) initiatives, underscoring the company's commitment to a sustainable future and a reduced environmental footprint.

Yahoo Finance
Jul 31st, 2025
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment.

Postmedia Network
Mar 28th, 2025
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category

For 14 years, Outsourced Pharma's CDMO Leadership Awards have recognized the top-performing contract development and manufacturing organizations based on comprehensive industry research, and feedback from sponsors.

BioSpace
May 29th, 2024
Altasciences Receives 2024 CRO Leadership Award for Capabilities

Altasciences receives 2024 CRO Leadership Award for Capabilities.

INACTIVE